 |
|
 |
|
  |
|
|
Updated: September 2021
With the emergence of COVID-19 [SARS-CoV-2] global pandemic in early 2020, and the rapid development of new vaccines, VacZine Analytics believes the development of further respiratory virus vaccines
has become more critical. Even prior to the pandemic, lower respiratory tract infections (LRTIs) were a leading cause of morbidity and mortality around the world with an estimated 2.3m deaths (GBD, 2016). In the worst case, this figure
may now double due to the SARS-CoV-2 coronavirus but this is dependent on the speed of deployment, real world effectiveness of global mass vaccination campaigns and virological parameters, especially genetic variation.
This brand new Respiratory virus vaccines report looks collectively at this overall market segment and covers 7 important respiratory pathogens including viruses such as seasonal influenza, respiratory syncytial virus (RSV),
SARS-CoV-2 [pandemic/seasonal], human metapneumovirus/PIV3 and others which will continue to dominate manufacturer R&D focus over the coming years. The report contains a comparative discussion of the global disease burden exerted by these pathogens, vaccine profiles (TPPs) with all relevant commercial
assumptions, competitive dynamics and POS/Non POS adjusted new vaccine revenue ($ 000s) forecasts per region (USA and Major 5 EU) to 2035. New product development is a report focus with an emphasis on mRNA candidates, multivalent approaches and marketing strategy.
It is an ideal analysis for those wishing to understand the key issues and longer term outlook for this important vaccine market segment.
THE FULL PRODUCT IS A SUMMARY PRESENTATION (~200 slides, .pdf form) + MS-WORKBOOK (.xls)
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*For more information about this product and how to order,
e-mail: orders@vaczine-analytics.com
For UK orders VAT will be added at 20%. TERMS and CONDITIONS of purchase will be made available upon enquiry.
| Documents on this page are available in Portable Document Format (PDF) 
|
|
|
|
|
|
